Rosiglitazone Inhibits Adrenocortical Cancer Cell Proliferation by Interfering with the IGF-IR Intracellular Signaling
Rosiglitazone (RGZ), a thiazolidinedione ligand of the peroxisome proliferator-activated receptor (PPAR)-γ, has been recently described as possessing antitumoral properties. We investigated RGZ effect on cell proliferation in two cell line models (SW13 and H295R) of human adrenocortical carcinoma (A...
Saved in:
| Main Authors: | Giulia Cantini, Adriana Lombardi, Elisabetta Piscitelli, Giada Poli, Elisabetta Ceni, Sara Marchiani, Tonino Ercolino, Andrea Galli, Mario Serio, Massimo Mannelli, Michaela Luconi |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2008-01-01
|
| Series: | PPAR Research |
| Online Access: | http://dx.doi.org/10.1155/2008/904041 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Emerging role of IGF1R and IR expression and localisation in adrenocortical carcinomas
by: Rosa Catalano, et al.
Published: (2025-03-01) -
Comparison of the Effectiveness of Insulin Sensitizing Agents Metformin and Rosiglitazone in PCOS
by: Rıfat Emral, et al.
Published: (2008-06-01) -
Effects of Metformin-Rosiglitazone on Glucose, Coagulation and Fibrinolysis among Diabetics
by: *Okungbowa, M. A. O. and Oyegue O. K.
Published: (2017-09-01) -
RP-HPLC Method for the Simultaneous Estimation of Rosiglitazone and Gliclazide in Tablets
by: G. Rathinavel, et al.
Published: (2009-01-01) -
Diagnosis and treatment of adrenocortical cancer
by: S. S. Kharnas, et al.
Published: (2013-06-01)